Compare MERC & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MERC | XLO |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 49.8M |
| IPO Year | 2005 | 2021 |
| Metric | MERC | XLO |
|---|---|---|
| Price | $0.73 | $9.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.25 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 384.5K | 27.3K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | $43,766,000.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.50 | ★ 589.88 |
| 52 Week Low | $0.71 | $0.46 |
| 52 Week High | $4.47 | $9.30 |
| Indicator | MERC | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 65.15 |
| Support Level | N/A | $7.47 |
| Resistance Level | $1.06 | $8.97 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 8.90 | 81.49 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.